Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis

John P. Bannantine, Murray E. Hines, Luiz E. Bermudez, Adel M. Talaat, Srinand Sreevatsan, Judith R. Stabel, Yung Fu Chang, Paul M. Coussens, Raul G Barletta, William C. Davis, Desmond M. Collins, Yrjo¨ T. Gro¨hn, Vivek Kapur

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The early 1980s, several investigations have focused on developing a vaccine against Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne's disease in cattle and sheep. These studies used whole-cell inactivated vaccines that have proven useful in limiting disease progression, but have not prevented infection. In contrast, modified live vaccines that invoke a Th1 type immune response, may improve protection against infection. Spurred by recent advances in the ability to create defined knockouts in MAP, several independent laboratories have developed modified live vaccine candidates by transpositional mutation of virulence and metabolic genes in MAP. In order to accelerate the process of identification and comparative evaluation of the most promising modified live MAP vaccine candidates, members of a multi-institutional USDA-funded research consortium, the Johne's disease integrated program (JDIP), met to establish a standardized testing platform using agreed upon protocols. A total of 22 candidates vaccine strains developed in five independent laboratories in the United States and New Zealand voluntarily entered into a double blind stage gated trial pipeline. In Phase I, the survival characteristics of each candidate were determined in bovine macrophages. Attenuated strains moved to Phase II, where tissue colonization of C57/BL6 mice were evaluated in a challenge model. In Phase III, five promising candidates from Phase I and II were evaluated for their ability to reduce fecal shedding, tissue colonization and pathology in a baby goat challenge model. Formation of a multi-institutional consortium for vaccine strain evaluation has revealed insights for the implementation of vaccine trials for Johne's disease and other animal pathogens. We conclude by suggesting the best way forward based on this 3-phase trial experience and challenge the rationale for use of a macrophage-to-mouse-to native host pipeline for MAP vaccine development.

Original languageEnglish (US)
Article numberArticle 126
JournalFrontiers in Cellular and Infection Microbiology
Volume4
Issue numberSEP
DOIs
StatePublished - Jan 1 2014

Fingerprint

Mycobacterium avium subsp. paratuberculosis
Vaccines
Paratuberculosis
Macrophages
United States Department of Agriculture
Inactivated Vaccines
Infection
New Zealand
Goats
Virulence
Disease Progression
Sheep
Pathology
Mutation

Keywords

  • Animal models
  • Attenuated
  • Genomics
  • Johne's disease
  • Mycobacterium
  • Transposons
  • Vaccines

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Bannantine, J. P., Hines, M. E., Bermudez, L. E., Talaat, A. M., Sreevatsan, S., Stabel, J. R., ... Kapur, V. (2014). Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis. Frontiers in Cellular and Infection Microbiology, 4(SEP), [Article 126]. https://doi.org/10.3389/fcimb.2014.00126

Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis. / Bannantine, John P.; Hines, Murray E.; Bermudez, Luiz E.; Talaat, Adel M.; Sreevatsan, Srinand; Stabel, Judith R.; Chang, Yung Fu; Coussens, Paul M.; Barletta, Raul G; Davis, William C.; Collins, Desmond M.; Gro¨hn, Yrjo¨ T.; Kapur, Vivek.

In: Frontiers in Cellular and Infection Microbiology, Vol. 4, No. SEP, Article 126, 01.01.2014.

Research output: Contribution to journalReview article

Bannantine, JP, Hines, ME, Bermudez, LE, Talaat, AM, Sreevatsan, S, Stabel, JR, Chang, YF, Coussens, PM, Barletta, RG, Davis, WC, Collins, DM, Gro¨hn, YT & Kapur, V 2014, 'Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis', Frontiers in Cellular and Infection Microbiology, vol. 4, no. SEP, Article 126. https://doi.org/10.3389/fcimb.2014.00126
Bannantine, John P. ; Hines, Murray E. ; Bermudez, Luiz E. ; Talaat, Adel M. ; Sreevatsan, Srinand ; Stabel, Judith R. ; Chang, Yung Fu ; Coussens, Paul M. ; Barletta, Raul G ; Davis, William C. ; Collins, Desmond M. ; Gro¨hn, Yrjo¨ T. ; Kapur, Vivek. / Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis. In: Frontiers in Cellular and Infection Microbiology. 2014 ; Vol. 4, No. SEP.
@article{6958734d5cdf4f5b89a2fa6b95dcb142,
title = "Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis",
abstract = "The early 1980s, several investigations have focused on developing a vaccine against Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne's disease in cattle and sheep. These studies used whole-cell inactivated vaccines that have proven useful in limiting disease progression, but have not prevented infection. In contrast, modified live vaccines that invoke a Th1 type immune response, may improve protection against infection. Spurred by recent advances in the ability to create defined knockouts in MAP, several independent laboratories have developed modified live vaccine candidates by transpositional mutation of virulence and metabolic genes in MAP. In order to accelerate the process of identification and comparative evaluation of the most promising modified live MAP vaccine candidates, members of a multi-institutional USDA-funded research consortium, the Johne's disease integrated program (JDIP), met to establish a standardized testing platform using agreed upon protocols. A total of 22 candidates vaccine strains developed in five independent laboratories in the United States and New Zealand voluntarily entered into a double blind stage gated trial pipeline. In Phase I, the survival characteristics of each candidate were determined in bovine macrophages. Attenuated strains moved to Phase II, where tissue colonization of C57/BL6 mice were evaluated in a challenge model. In Phase III, five promising candidates from Phase I and II were evaluated for their ability to reduce fecal shedding, tissue colonization and pathology in a baby goat challenge model. Formation of a multi-institutional consortium for vaccine strain evaluation has revealed insights for the implementation of vaccine trials for Johne's disease and other animal pathogens. We conclude by suggesting the best way forward based on this 3-phase trial experience and challenge the rationale for use of a macrophage-to-mouse-to native host pipeline for MAP vaccine development.",
keywords = "Animal models, Attenuated, Genomics, Johne's disease, Mycobacterium, Transposons, Vaccines",
author = "Bannantine, {John P.} and Hines, {Murray E.} and Bermudez, {Luiz E.} and Talaat, {Adel M.} and Srinand Sreevatsan and Stabel, {Judith R.} and Chang, {Yung Fu} and Coussens, {Paul M.} and Barletta, {Raul G} and Davis, {William C.} and Collins, {Desmond M.} and Gro¨hn, {Yrjo¨ T.} and Vivek Kapur",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fcimb.2014.00126",
language = "English (US)",
volume = "4",
journal = "Frontiers in cellular and infection microbiology",
issn = "2235-2988",
publisher = "Frontiers Media S. A.",
number = "SEP",

}

TY - JOUR

T1 - Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis

AU - Bannantine, John P.

AU - Hines, Murray E.

AU - Bermudez, Luiz E.

AU - Talaat, Adel M.

AU - Sreevatsan, Srinand

AU - Stabel, Judith R.

AU - Chang, Yung Fu

AU - Coussens, Paul M.

AU - Barletta, Raul G

AU - Davis, William C.

AU - Collins, Desmond M.

AU - Gro¨hn, Yrjo¨ T.

AU - Kapur, Vivek

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The early 1980s, several investigations have focused on developing a vaccine against Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne's disease in cattle and sheep. These studies used whole-cell inactivated vaccines that have proven useful in limiting disease progression, but have not prevented infection. In contrast, modified live vaccines that invoke a Th1 type immune response, may improve protection against infection. Spurred by recent advances in the ability to create defined knockouts in MAP, several independent laboratories have developed modified live vaccine candidates by transpositional mutation of virulence and metabolic genes in MAP. In order to accelerate the process of identification and comparative evaluation of the most promising modified live MAP vaccine candidates, members of a multi-institutional USDA-funded research consortium, the Johne's disease integrated program (JDIP), met to establish a standardized testing platform using agreed upon protocols. A total of 22 candidates vaccine strains developed in five independent laboratories in the United States and New Zealand voluntarily entered into a double blind stage gated trial pipeline. In Phase I, the survival characteristics of each candidate were determined in bovine macrophages. Attenuated strains moved to Phase II, where tissue colonization of C57/BL6 mice were evaluated in a challenge model. In Phase III, five promising candidates from Phase I and II were evaluated for their ability to reduce fecal shedding, tissue colonization and pathology in a baby goat challenge model. Formation of a multi-institutional consortium for vaccine strain evaluation has revealed insights for the implementation of vaccine trials for Johne's disease and other animal pathogens. We conclude by suggesting the best way forward based on this 3-phase trial experience and challenge the rationale for use of a macrophage-to-mouse-to native host pipeline for MAP vaccine development.

AB - The early 1980s, several investigations have focused on developing a vaccine against Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne's disease in cattle and sheep. These studies used whole-cell inactivated vaccines that have proven useful in limiting disease progression, but have not prevented infection. In contrast, modified live vaccines that invoke a Th1 type immune response, may improve protection against infection. Spurred by recent advances in the ability to create defined knockouts in MAP, several independent laboratories have developed modified live vaccine candidates by transpositional mutation of virulence and metabolic genes in MAP. In order to accelerate the process of identification and comparative evaluation of the most promising modified live MAP vaccine candidates, members of a multi-institutional USDA-funded research consortium, the Johne's disease integrated program (JDIP), met to establish a standardized testing platform using agreed upon protocols. A total of 22 candidates vaccine strains developed in five independent laboratories in the United States and New Zealand voluntarily entered into a double blind stage gated trial pipeline. In Phase I, the survival characteristics of each candidate were determined in bovine macrophages. Attenuated strains moved to Phase II, where tissue colonization of C57/BL6 mice were evaluated in a challenge model. In Phase III, five promising candidates from Phase I and II were evaluated for their ability to reduce fecal shedding, tissue colonization and pathology in a baby goat challenge model. Formation of a multi-institutional consortium for vaccine strain evaluation has revealed insights for the implementation of vaccine trials for Johne's disease and other animal pathogens. We conclude by suggesting the best way forward based on this 3-phase trial experience and challenge the rationale for use of a macrophage-to-mouse-to native host pipeline for MAP vaccine development.

KW - Animal models

KW - Attenuated

KW - Genomics

KW - Johne's disease

KW - Mycobacterium

KW - Transposons

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84907063054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907063054&partnerID=8YFLogxK

U2 - 10.3389/fcimb.2014.00126

DO - 10.3389/fcimb.2014.00126

M3 - Review article

C2 - 25250245

AN - SCOPUS:84907063054

VL - 4

JO - Frontiers in cellular and infection microbiology

JF - Frontiers in cellular and infection microbiology

SN - 2235-2988

IS - SEP

M1 - Article 126

ER -